An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial

PURPOSE: A recent phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki disease (KD) patients reported promising results. Here, we aimed to characterize the immunological impact of IL-1 blockade in this unique study population...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessel, Christoph, Koné-Paut, Isabelle, Tellier, Stéphanie, Belot, Alexandre, Masjosthusmann, Katja, Wittkowski, Helmut, Fuehner, Sabrina, Rossi-Semerano, Linda, Dusser, Perrine, Marie, Isabelle, Boukhedouni, Nadja, Agostini, Helène, Piedvache, Céline, Foell, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537216/
https://www.ncbi.nlm.nih.gov/pubmed/35699824
http://dx.doi.org/10.1007/s10875-022-01301-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537216/
https://www.ncbi.nlm.nih.gov/pubmed/35699824
http://dx.doi.org/10.1007/s10875-022-01301-w

Ejemplares similares